147 related articles for article (PubMed ID: 12710205)
1. Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
Adjei AA
Methods Mol Med; 2003; 85():141-5. PubMed ID: 12710205
[No Abstract] [Full Text] [Related]
2. Comparison of potential markers of farnesyltransferase inhibition.
Adjei AA; Davis JN; Erlichman C; Svingen PA; Kaufmann SH
Clin Cancer Res; 2000 Jun; 6(6):2318-25. PubMed ID: 10873082
[TBL] [Abstract][Full Text] [Related]
3. Dual protein farnesyltransferase-geranylgeranyltransferase-I inhibitors as potential cancer chemotherapeutic agents.
deSolms SJ; Ciccarone TM; MacTough SC; Shaw AW; Buser CA; Ellis-Hutchings M; Fernandes C; Hamilton KA; Huber HE; Kohl NE; Lobell RB; Robinson RG; Tsou NN; Walsh ES; Graham SL; Beese LS; Taylor JS
J Med Chem; 2003 Jul; 46(14):2973-84. PubMed ID: 12825937
[TBL] [Abstract][Full Text] [Related]
4. 2-substituted piperazines as constrained amino acids. Application to the synthesis of potent, non carboxylic acid inhibitors of farnesyltransferase.
Williams TM; Ciccarone TM; MacTough SC; Bock RL; Conner MW; Davide JP; Hamilton K; Koblan KS; Kohl NE; Kral AM; Mosser SD; Omer CA; Pompliano DL; Rands E; Schaber MD; Shah D; Wilson FR; Gibbs JB; Graham SL; Hartman GD; Oliff AI; Smith RL
J Med Chem; 1996 Mar; 39(7):1345-8. PubMed ID: 8691462
[No Abstract] [Full Text] [Related]
5. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2002; 20():151-67. PubMed ID: 12703204
[No Abstract] [Full Text] [Related]
6. Farnesyltransferase inhibitors.
Adjei AA
Cancer Chemother Biol Response Modif; 2001; 19():149-64. PubMed ID: 11686012
[No Abstract] [Full Text] [Related]
7. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
[TBL] [Abstract][Full Text] [Related]
8. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
[No Abstract] [Full Text] [Related]
9. The development of protein farnesyltransferase inhibitors as signaling-based anticancer agents.
Ohkanda J; Blaskovich MA; Sebti SM; Hamilton AD
Prog Cell Cycle Res; 2003; 5():211-7. PubMed ID: 14593715
[TBL] [Abstract][Full Text] [Related]
10. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
11. Actin' up: RhoB in cancer and apoptosis.
Prendergast GC
Nat Rev Cancer; 2001 Nov; 1(2):162-8. PubMed ID: 11905808
[TBL] [Abstract][Full Text] [Related]
12. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
[TBL] [Abstract][Full Text] [Related]
13. 2-Arylindole-3-acetamides: FPP-competitive inhibitors of farnesyl protein transferase.
Trotter BW; Quigley AG; Lumma WC; Sisko JT; Walsh ES; Hamann CS; Robinson RG; Bhimnathwala H; Kolodin DG; Zheng W; Buser CA; Huber HE; Lobell RB; Kohl NE; Williams TM; Graham SL; Dinsmore CJ
Bioorg Med Chem Lett; 2001 Apr; 11(7):865-9. PubMed ID: 11294379
[TBL] [Abstract][Full Text] [Related]
14. Emerging treatments in acute myeloid leukaemia.
Kell J
Expert Opin Emerg Drugs; 2004 May; 9(1):55-71. PubMed ID: 15155136
[TBL] [Abstract][Full Text] [Related]
15. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors in breast cancer therapy.
Dy GK; Adjei AA
Cancer Invest; 2002; 20 Suppl 2():30-7. PubMed ID: 12442347
[TBL] [Abstract][Full Text] [Related]
17. An antibody which specifically recognizes prelamin A but not mature lamin A: application to detection of blocks in farnesylation-dependent protein processing.
Sinensky M; Fantle K; Dalton M
Cancer Res; 1994 Jun; 54(12):3229-32. PubMed ID: 8205544
[TBL] [Abstract][Full Text] [Related]
18. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Sun J; Ohkanda J; Coppola D; Yin H; Kothare M; Busciglio B; Hamilton AD; Sebti SM
Cancer Res; 2003 Dec; 63(24):8922-9. PubMed ID: 14695209
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and antiproliferative activity of N-acylaspartic acid dimethyl esters.
Schlitzer M; Sattler I; Dahse HM
Anticancer Res; 1999; 19(3A):2117-20. PubMed ID: 10470158
[TBL] [Abstract][Full Text] [Related]
20. Protein farnesyltransferase inhibitors and progeria.
Meta M; Yang SH; Bergo MO; Fong LG; Young SG
Trends Mol Med; 2006 Oct; 12(10):480-7. PubMed ID: 16942914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
